

## HIV Attachment B - Preliminary List of Pharmaceuticals, Health Products and Health Equipment

Applicant Name :	Country Coordinating Mechanism
Country :	Malaysia
Definitions used in this attachment:	
INN	International Nonproprietary Names
EML	Essential Medicines List
STG	Standard Treatment Guidelines
	No information required for this cell

**Table B.1 - List of Key Pharmaceutical Products included the Proposal**

Product Category	INN / Generic Product Name <i>(Insert full name not treatment regime formula)</i>	Strength	WHO List (Year updated _____ )		National List (Year updated _____ )		Institutional List (Year updated _____ )	
			EML (Yes/No)	STG (Yes/No)	EML (Yes/No)	STG (Yes/No)	EML (Yes/No)	STG (Yes/No)
First Line ARVs for Adults								
Pediatric First Line ARVs								
Second Line ARVs for Adults								
Pediatric Second Line ARVs								
Medicines for PEP, incl PMTCT services								

## HIV Attachment B - Preliminary List of Pharmaceuticals, Health Products and Health Equipment

<b>Applicant Name :</b>	Country Coordinating Mechanism
<b>Country :</b>	Malaysia

Table B.2 - Estimated Year 1 and Year 2 Costs for Pharmaceutical Products included in the Proposal						Please specify the INCOTERM used :			
Product Category	INN / Generic Product Name <small>(Insert full name not treatment regime formula)</small>	Strength	Unit <small>(per tab, per inj, per ml/pack size)</small>	Estimated cost per unit <small>(same currency as proposal)</small>	Year One Quantity <small>(no. of units)</small>	Year One Total Cost	Year Two Quantity <small>(no. of units)</small>	Year Two Total Cost	Cumulative Two Year Budget
First Line ARVs for Adults									
Pediatric First Line ARVs									
Second Line ARVs for Adults									
Pediatric Second Line ARVs									
Medicines for PEP, incl PMTCT services									
Other medicines* <small>(e.g. treatments for opportunistic infections &amp; STIs, management of side-effects, substitution therapy for IDUs)</small>									
<b>SUB-TOTALS (automatically completed) ==&gt;</b>									

\* Please provide only the total cost for "other medicines" category for year 1 and year 2. If the list of items is long you can attach the detailed list of items to this attachment B

## HIV Attachment B - Preliminary List of Pharmaceuticals, Health Products and Health Equipment

Applicant Name :	Country Coordinating Mechanism
Country :	Malaysia

**Table B.3 - Estimated Year 1 and Year 2 Costs of Health Products and Health Equipment and of Infrastructure and Other Equipment**

Product Category	Product Name	Estimated cost per unit (same currency as proposal)	Estimated Year One Quantity	Year One Total Cost	Estimated Year Two Quantity	Year Two Total Cost	Cumulative Two Year Budget
Health Products (incl consumables: e.g., diagnostics, condoms, gloves and syringes.)	Condoms	0.0300	1500000	45000.00	1500000	45000.00	90000.00
	Lubricant	0.0600	1500000	90000.00	1500000	90000.00	180000.00
	Syringe Kits	0.7300	250000	182500.00	500000	365000.00	547500.00
Health Equipment ** (e.g., microscopes, CD4 count machine, x-ray equipment).							
<b>SUB-TOTALS (automatically completed) ==&gt;</b>				317500.00		500000.00	817500.00

\*\* Note: For Health Equipment, the costing provided in the table above should take into account the "total cost of ownership" (TCO). TCO includes the cost of reagents and annual maintenance to ensure the equipment operates effectively.

**Table B.4 - List of Services directly tied to Management of Pharmaceuticals, Health Products and Health Equipment**

Description of the Service*** (e.g. for MIS systems, QA system strengthening, QC Testing, pharmacovigilance)	Related budget cost category***	Year One Quantity	Year One Total Cost	Year Two Quantity	Year Two Total Cost	Cumulative Two Year Budget
<b>SUB-TOTALS (automatically completed) ==&gt;</b>						

\*\*\* Please detail all services linked to management of pharmaceuticals, health products and health equipment and indicate the related budget cost category described in the Proposal Guidelines

Sources and Prices of Selected Drugs and Diagnostics for People Living with HIV/AIDS. Copenhagen/Geneva, UNAIDS/UNICEF/WHO-HTP/MSF, June 2005, (<http://www.who.int/medicines/organization/par/ipc/sources-prices.pdf>); International Drug Price Indicator Guide on Finished Products of Essential Drugs, Management Sciences for Health in Collaboration with WHO (published annually) (<http://www.msh.org>), • Untangling the Web of Price Reduction, 10th edition. Médecins Sans Frontières. July 2007. (available at: [http://www.msf.or.jp/pressroom/img\\_press\\_report/pdf/Untangling\\_10th\\_edition\\_July2007.pdf](http://www.msf.or.jp/pressroom/img_press_report/pdf/Untangling_10th_edition_July2007.pdf))